Withdrã wn 2.0-updat e on withdrã wn drugs with pharmacovigilance data

Abstract

One challenge in the de v elopment of no v el drugs is their interaction with potential off-targets, which can cause unintended side-effects, that can lead to the subsequent withdra wãl ofãppro v ed drugs. At the same time, these off-targets mayãlso presentã chance for the repositioning of withdra wn drugs f or ne w indications, whichãre potentially rare or more se v ere than the original indicationãnd where certainãdverse reactions may beãvoidable or tolerable. To enable further insights into this topic, we updated our database Withdrawn byãdding pharmacovigilance data from the FDA A dv erse Ev ent R eporting Sy stem (FAER S),ãs w ellãs mechanism ofãctionãnd human disease pathwã y prediction features f or drugs thatãre or were temporarily withdrawn or discontinued inãt least one country. As withdra wãl dataãre still spread o v er doz ens of national w ebsites, w eãre continuously updating our lists of discontinued or withdrawn drugsãnd related (off-)targets. Furthermore, new systematic entry points f or bro wsing the data, suchãsãn ATC tree, wereãdded, increasing theãccessibility of the database inã user-friendly wã y. Withdra wn 2.0 is publiclyã vãilable without the need for registration or loginãt ht tps://bioinformatics.c harite.de/ withdrawn _ 3/ index.php .